Evotec (NASDAQ:EVO) Hits New 1-Year Low – Time to Sell?

Evotec AG (NASDAQ:EVO) reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $2.15 and last traded at $2.16, with a volume of 106040 shares traded. The stock had previously closed at $2.43.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. TD Cowen downgraded shares of Evotec from a “buy” rating to a “hold” rating and set a $2.00 price objective on the stock. in a research report on Wednesday. HC Wainwright cut their target price on shares of Evotec from $7.00 to $4.00 and set a “buy” rating for the company in a research report on Wednesday. Weiss Ratings raised shares of Evotec from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, April 24th. Finally, Wall Street Zen cut shares of Evotec from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Evotec presently has a consensus rating of “Hold” and a consensus target price of $3.00.

Evotec Price Performance

The company has a fifty day moving average price of $2.79 and a 200-day moving average price of $3.03. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.60 and a current ratio of 1.68.

Evotec (NASDAQ:EVO) last released its quarterly earnings data on Tuesday, March 31st. The company reported $0.05 EPS for the quarter. The firm had revenue of $297.02 million for the quarter. Evotec had a negative return on equity of 24.93% and a negative net margin of 26.20%. Equities analysts expect that Evotec AG will post -0.63 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of EVO. Wellington Management Group LLP lifted its stake in shares of Evotec by 25.7% in the 4th quarter. Wellington Management Group LLP now owns 1,797,444 shares of the company’s stock valued at $5,536,000 after purchasing an additional 367,545 shares during the last quarter. WCM Investment Management LLC lifted its position in shares of Evotec by 12.1% in the first quarter. WCM Investment Management LLC now owns 627,260 shares of the company’s stock worth $1,480,000 after buying an additional 67,917 shares during the last quarter. ABC Arbitrage SA boosted its stake in shares of Evotec by 319.7% during the 4th quarter. ABC Arbitrage SA now owns 554,287 shares of the company’s stock worth $1,707,000 after acquiring an additional 422,230 shares in the last quarter. Optiver Holding B.V. increased its holdings in shares of Evotec by 598.4% during the 1st quarter. Optiver Holding B.V. now owns 283,576 shares of the company’s stock valued at $709,000 after acquiring an additional 242,973 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of Evotec during the 4th quarter valued at about $565,000. Institutional investors own 5.81% of the company’s stock.

Evotec Company Profile

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.